Strides Pharma Science Ltd

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Strides Pharma Science announced that the 35th Annual General Meeting(AGM) of the company will be held on 14 August 2026.

Strides Pharma Science has fixed 31 July 2026 as the record date for determining the entitlement of shareholders to receive final dividend of Rs 5 per equity share for FY 2026.

The transaction values Pivot Path at Rs 230 crore on a post-money basis. This would enable Strides to realise Rs 100 crore while retaining a 20% stake. The deal also includes a primary capital infusion of Rs 50 crore to accelerate Pivot Path's next phase of growth. Pivot Path originated within Arco Lab, Strides' Global Capability Centre (GCC), where it developed capabilities across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. As demand from external pharmaceutical and life sciences companies grew, the business evolved into an independent platform serving industry-leading customers. To support its next phase of growth, serve global customers effectively, build agentic-AI platforms, and enable access to external capital, the business was carved out into Pivot Path. Pivot Path has established a profitable operating platform serving specialised, high-value segments within the life sciences industry. For FY26, the carved-out business reported revenue of Rs 144.7 crore and EBITDA of Rs 16.9 crore. Following completion of the transaction Pivot Path shall be reclassified as an associate of Strides Pharma. Badree Komandur, MD & Group CEO of Strides, said: 'Pivot Path exemplifies Strides' proven capability to identify, incubate and scale high-potential businesses. Over the past years, we have built a platform with specialised capabilities, a growing customer base and a strong foundation for future growth. As the business enters its next phase, we believe this is the right time to bring in a strategic investment partner with the expertise and capital to accelerate its growth.' Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products. The company had reported 54.44% surge in consolidated net profit to Rs 126.94 crore in Q4 FY26 as against Rs 82.19 crore in Q4 FY25. Revenue from operations rose 11.17% YoY to Rs 1,323.47 crore in the quarter ended 31 March 2026. Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 54.45% to Rs 126.94 crore in the quarter ended March 2026 as against Rs 82.19 crore during the previous quarter ended March 2025. Sales rose 11.18% to Rs 1323.47 crore in the quarter ended March 2026 as against Rs 1190.39 crore during the previous quarter ended March 2025. For the full year,net profit declined 84.52% to Rs 556.19 crore in the year ended March 2026 as against Rs 3593.46 crore during the previous year ended March 2025. Sales rose 6.43% to Rs 4858.68 crore in the year ended March 2026 as against Rs 4565.34 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1323.471190.39 11 4858.684565.34 6 OPM %18.1118.30 -19.0417.58 - PBDT207.71182.66 14 897.93614.52 46 PBT154.46133.80 15 695.53422.26 65 NP126.9482.19 54 556.193593.46 -85 Powered by Capital Market - Live

Revenue from operations rose 11.17% YoY to Rs 1,323.47 crore in the quarter ended 31 March 2026. Profit before exceptional items and tax increased 17.09% YoY to Rs 153.01 crore, while the company also reported an exceptional loss of Rs 6.41 crore during the quarter. EBITDA stood at Rs 239.7 crore in Q4 FY26, registering a growth of 10% compared with Rs 217.9 crore in Q4 FY25. EBITDA margin declined by 20 basis points to 18.1% in Q4 FY26, as against 18.3% in Q4 FY25. For the full financial year FY26, the company reported an 84.52% tumble in net profit to Rs 556.19 crore, compared with Rs 556.19 crore in the previous year. Revenue from operations rose 6.42% to Rs 4,858.68 crore in FY26. For the full year, the company's US market revenue stood at Rs 2,489.7 crore, growing 2% year-on-year, while Ex-US market revenue rose sharply by 21% to Rs 2,240.4 crore, emerging as the key growth driver for the business. The company reported net debt of Rs 1,436.5 crore, impacted by forex depreciation of Rs 111.5 crore. Net debt-to-EBITDA improved to 1.55x in FY26 from 1.9x in FY25, while RoCE rose to 15.8% from 14.9%. Badree Komandur, MD & Group CEO, said, 'Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex‑US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex‑US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth.' Meanwhile, the company's board has recommended a final dividend of Rs 5 per equity share of face value Rs 10 each, representing 50% of the face value, for the financial year ended 31 March 2026. The record date for determining shareholders eligible for the dividend will be fixed and intimated in due course. The dividend, subject to shareholders' approval at the ensuing Annual General Meeting (AGM), will be paid within 30 days from the date of approval after deduction of applicable tax at source. Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products. Powered by Capital Market - Live

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 18 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 18 May 2026.

In a regulatory filing made after market hours yesterday, the company informed that its step- down subsidiary, Strides Pharma International AG (SPIAG) has entered into definitive agreements with Sandoz AG, Switzerland, for the acquisition and in-licensing of a portfolio of branded generic products across Sub Saharan Africa (SSA). The agreement spans four key markets, which include Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti-infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding $1 million, reflecting their established brand equity and market demand. The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz. To ensure the uninterrupted availability of these critical brands, Strides will also enter into a manufacturing and supply agreement with Sandoz for their continued production and supply. With the combined strength of Strides' existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the SSA region by sales and among the top two players in the representable market. Strides Pharma further said that the initial consideration for the transaction is $12 million, payable at closing and is expected to be funded through internal accruals. The arrangement also provides for yearly royalty payments to the Sandoz based on a percentage of net sales for the distribution products. The transaction is expected to be EPS accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage. The transaction is expected to close by the end of Q2 FY27 (quarter ending 30 September 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions. Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company focused on regulated and emerging markets, with manufacturing facilities across India, Italy, Kenya and the US, and a presence in over 100 countries. On a consolidated basis, the company's profit after tax rose 131.14% YoY to Rs 208.12 crore in Q3 FY26 from Rs 90.04 crore a year ago. Revenue increased 3.6% YoY to Rs 1,194.6 crore in Q3 FY26. Powered by Capital Market - Live

Strides Pharma Science announced that Strides Pharma Inc. (SPI), a step-down wholly owned subsidiary of the Company in the USA, has received the USFDA Inspection Closure Report (Establishment Inspection Report - EIR) for its Formulations Facility located at Chestnut Ridge, New York, USA. The Facility was inspected by the United States Food and Drug Administration (USFDA) from 17 December 2025 to 23 December 2025. The inspection covered current Good Manufacturing Practices (cGMP) and included a pre-approval inspection for Drug-Device Combination capabilities, covering the Company's recent filing in Nasal Sprays domain. Based on SPI's response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (Voluntary Ac on Indicated). The EIR states that the inspection has been closed. The Chestnut Ridge facility caters to the U.S. market and manufactures Liquids, Gels, Hormones, Modified Release products and Controlled Substances, supporting several current and future products for the U.S. market. The successful closure of this inspection including Device Combinations further strengthens the Company's U.S. business and near term growth prospects.Powered by Capital Market - Live